Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine

被引:120
作者
Bellmunt, J
Albanell, J
Paz-Ares, L
Climent, MA
González-Larriba, JL
Carles, J
de la Cruz, JJ
Guillem, V
Díaz-Rubio, E
Cortés-Funes, H
Baselga, J
机构
[1] Vall Hebron Univ Hosp, Med Oncol Sect, Barcelona 08035, Spain
[2] Hosp 12 Octubre, E-28041 Madrid, Spain
[3] Inst Valenciano Oncol, Valencia, Spain
[4] Hosp Clin Madrid, Madrid, Spain
[5] Hosp del Mar, Barcelona, Spain
[6] Univ Autonoma Madrid, Madrid, Spain
关键词
prognostic factors; advanced urothelial tumors; transitional cell carcinoma; paclitaxel; cisplatin; gemcitabine; chemotherapy;
D O I
10.1002/cncr.10762
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND. New chemotherapeutic agents, including paclitaxel and gemcitabine, are active in advanced bladder carcinoma, and combination regimens with these agents have shown promising results. Unlike conventional chemotherapy regimens, such as methotrexate, vinblastine, doxorubicin, and cisplatin, there are no data available on key predictive factors for response and survival with these novel agents. Since this information is needed for selection of patients for these new combinations and for stratification purposes in ongoing randomized trials, the authors aimed to study the predictive factors for response and survival to the current regimen containing cisplatin, paclitaxel, and gemcitabine. METHODS. The authors studied 56 patients with advanced urothelial tumors treated on a Phase I/II trial of paclitaxel, cisplatin, and gemcitabine (TCG) to identify pretreatment characteristics that were prognostic for survival using this novel combination. The pretreatment characteristics analyzed were age, gender, Eastern Cooperative Oncology Group performance status, histopathology (pure transitional versus other), visceral (liver, lung, or bone) nietastasis, number of sites of disease, lactate dehydrogenase, and hemoglobin. RESULTS. The factors that were associated with a worse survival in univariate analysis were performance status > 0, presence of visceral metastasis, and more than one site of malignant disease. In a multivariate model, performance status (P = 0.044) and visceral disease (P = 0.008) showed independent statistical significance for decreased survival. Patients were then grouped based on these two independent prognostic factors. Median survival times in the groups of patients with zero, one, or two of these risk factors were 32.8 months, 17 months, and 9.6 months, respectively (P = 0.0005). CONCLUSIONS. A pretreatment performance status > 0 and the presence of visceral metastasis have a profound impact on survival when using the TCG regimen. These two variables will be used to stratify patients in the upcoming Phase III randomized trial comparing this TGC regimen with a gemcitabine/cisplatin regimen in advanced urothelial tumors. (C) 2002 American Cancer Society.
引用
收藏
页码:751 / 757
页数:7
相关论文
共 29 条
[1]   Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy [J].
Bajorin, DF ;
Dodd, PM ;
Mazumdar, M ;
Fazzari, M ;
McCaffrey, JA ;
Scher, HI ;
Herr, H ;
Higgins, G ;
Boyle, MG .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (10) :3173-3181
[2]   Treatment of patients with transitional-cell carcinoma of the urothelial tract with ifosfamide, paclitaxel, and cisplatin: A phase II trial [J].
Bajorin, DF ;
McCaffrey, JA ;
Hilton, S ;
Mazumdar, M ;
Kelly, WK ;
Scher, HI ;
Spicer, J ;
Herr, H ;
Higgins, G .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (08) :2722-2727
[3]   Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium [J].
Bellmunt, J ;
Guillem, V ;
Paz-Ares, L ;
González-Larriba, JL ;
Carles, J ;
Batiste-Alentorn, E ;
Sáenz, A ;
López-Brea, M ;
Font, A ;
Nogué, M ;
Bastús, R ;
Climent, MA ;
de la Cruz, JJ ;
Albanell, J ;
Banús, JM ;
Gallardo, E ;
Diaz-Rubio, E ;
Cortés-Funes, H ;
Baselga, J .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (18) :3247-3255
[4]  
Burch PA, 2000, J UROLOGY, V164, P1538, DOI 10.1016/S0022-5347(05)67023-1
[5]   Phase II study of cisplatin and paclitaxel in advanced carcinoma of the urothelium: An Eastern Cooperative Oncology Group study [J].
Dreicer, R ;
Manola, J ;
Roth, BJ ;
Cohen, MB ;
Hatfield, AK ;
Wilding, G .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (05) :1058-1061
[6]  
Droz JP, 1998, P AN M AM SOC CLIN, V17, p316a
[7]   Phase I/II study of paclitaxel, carboplatin, and methotrexate in advanced transitional cell carcinoma: A well-tolerated regimen with activity independent of p53 mutation [J].
Edelman, MJ ;
Meyers, FJ ;
Miller, TR ;
Williams, SG ;
Gandour-Edwards, R ;
White, RWD .
UROLOGY, 2000, 55 (04) :521-525
[8]  
GELLER NL, 1991, CANCER-AM CANCER SOC, V67, P1525, DOI 10.1002/1097-0142(19910315)67:6<1525::AID-CNCR2820670611>3.0.CO
[9]  
2-8
[10]   CISPLATIN, METHOTREXATE, AND VINBLASTINE (CMV) - AN EFFECTIVE CHEMOTHERAPY REGIMEN FOR METASTATIC TRANSITIONAL CELL-CARCINOMA OF THE URINARY-TRACT - A NORTHERN-CALIFORNIA-ONCOLOGY-GROUP STUDY [J].
HARKER, WG ;
MEYERS, FJ ;
FREIHA, FS ;
PALMER, JM ;
SHORTLIFFE, LD ;
HANNIGAN, JF ;
MCWHIRTER, KM ;
TORTI, FM .
JOURNAL OF CLINICAL ONCOLOGY, 1985, 3 (11) :1463-1470